

Press release
Lund, December 19, 2012

Enzymatica signs agreement with the Kronans Droghandel pharmacy chain.

Enzymatica has concluded its first commercial agreement. This entails that Enzymatica's medical device product, ColdZyme® Mouth Spray used against the common cold, will be on sale at the Kronans Droghandel pharmacies in early 2013.

“The agreement is, of course, commercially important for us, since the pharmacy chains represent a significant factor in our launch strategy. It has been consistently our goal to launch among the pharmacy chains at the beginning of 2013 and thus it is extra gratifying to be able to deliver on schedule,” says Michael Edelborg Christensen, CEO at Enzymatica.

The agreement means Enzymatica's registered product, ColdZyme® Mouth Spray, will be on sale at the Kronans Droghandel pharmacies nationwide. The launch of the ColdZyme® Mouth Spray is expected to take place at the end of January 2013.

“That we have in such a short period from the registration of the product secured the first agreement with a major pharmacy chain, we regard as a stamp of quality for our products and confirmation of the market potential. Negotiations with other pharmacy chains are proceeding as planned,” notes Michael Edelborg Christensen.

For more information, contact:

Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
michael.christensen@enzymatica.se

Andreas Rosenlund, Director of Information at Kronans Droghandel, 0703-59 10 58
andreas.rosenlund@kronansdroghandel.se

Kronans Droghandel in brief

Kronans Droghandel is Sweden's third largest pharmacy chain, with more than 215 pharmacies from Trelleborg in the south to Malmberget in the north. Kronans Droghandel was established in 1907 at the Apoteket Kronan pharmacy in Gothenburg, but can trace its origins back to the 17th century. Kronans Droghandel, which is owned by Oriola-KD, has some 1,300 employees.

About Enzymatica AB (publ)

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and registration of medical devices based on patented enzyme technology. Enzymatica utilizes a cold-adapted trypsin derived from deep-sea cod. The enzyme has a unique property that makes it super-active at about 37° C, making it superior in breaking down illness-related proteins, counteracting viral and bacterial infections and promoting healing processes. The ColdZyme[®] portfolio, which is currently available at health care stores, contains the predecessors to the products that are now registered as medical devices to treat the common cold, as well as dental/oral cavity disorders.

About the ColdZyme[®] Mouth Spray

ColdZyme[®] Mouth Spray is a medical device product, Class 1 (CE marked). The ColdZyme[®] Mouth Spray reduces the risk of contracting a cold and/or shortens the illness period at an early stage of the infection by creating a barrier of thin protecting film in the throat.

About Enzymatica on the web

[Enzymatica Newsdesk »](#)

[Enzymatica Website »](#)

[Enzymatica on LinkedIn »](#)

[Enzymatica on Twitter »](#)

[For Investors »](#)

[ColdZyme Website »](#)

[ColdZyme on facebook »](#)